TP53 and ovarian cancer: Moreover, compared with low expression of PTGIS, elevated expression of PTGIS was revealed to be associated with poorer survival outcomes for patients with stage 3 disease, patients with wild-type TP53, and patients treated with suboptimal debulking surgery in ovarian cancer, as well as for patients with advanced-stage disease or lymph node metastasis in gastric cancer.